<SEC-DOCUMENT>0001683168-22-005187.txt : 20220728
<SEC-HEADER>0001683168-22-005187.hdr.sgml : 20220728
<ACCEPTANCE-DATETIME>20220728171442
ACCESSION NUMBER:		0001683168-22-005187
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20220728
DATE AS OF CHANGE:		20220728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PharmaCyte Biotech, Inc.
		CENTRAL INDEX KEY:			0001157075
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621772151
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40699
		FILM NUMBER:		221116220

	BUSINESS ADDRESS:	
		STREET 1:		23046 AVENIDA DE LA CARLOTA, SUITE 600
		CITY:			LAGUNA HILLS
		STATE:			CA
		ZIP:			92653
		BUSINESS PHONE:		(917) 595.2850

	MAIL ADDRESS:	
		STREET 1:		23046 AVENIDA DE LA CARLOTA, SUITE 600
		CITY:			LAGUNA HILLS
		STATE:			CA
		ZIP:			92653

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVILEX, INC.
		DATE OF NAME CHANGE:	20090324

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EFOODSAFETY COM INC
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>pharmacyte_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>

</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Form 8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Current Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event
reported): <FONT STYLE="text-decoration: underline">July
28, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B><U>PHARMACYTE
BIOTECH, INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><FONT STYLE="text-decoration: underline">Nevada</FONT></B></FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><FONT STYLE="text-decoration: underline">001-40699</FONT></B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><FONT STYLE="text-decoration: underline">62-1772151</FONT></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(I.R.S. Employer Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3960
    Howard Hughes Parkway, Suite
    500<BR> Las Vegas, Nevada</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>89169</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Address of Principal Executive Offices)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Zip Code)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&#160;</TD>
    <TD STYLE="text-align: center">&#160;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant's telephone number, including area code:
<B>(917) 595-2850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-decoration: underline">N/A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &#9744; Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &#9746; Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9744; Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9744; Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title of each class</FONT></TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 34%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of exchange on which registered</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common Stock, Par Value $0.0001 Per Share</FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">PMCB</FONT></TD>
    <TD>&#160;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The Nasdaq
Stock Market LLC</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this Chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 73px"><B>Item 8.01</B></TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt"><B> Other Events.</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 28, 2022, PharmaCyte Biotech, Inc. (&ldquo;PharmaCyte&rdquo;
or the &ldquo;Company&rdquo;) issued a press release rebuking the commencement of a consent solicitation by Iroquois Capital Management,
LLC and its affiliates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Important Additional Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, its directors and certain of its
executive officers are participants in the solicitation of proxies from the Company&rsquo;s shareholders in connection with the Company&rsquo;s
2022 Annual Meeting of Stockholders. The Company intends to file a definitive proxy statement and a WHITE proxy card with the Securities
and Exchange Commission (&ldquo;SEC&rdquo;) in connection with any such solicitation of proxies from the Company&rsquo;s stockholders.
STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH PROXY STATEMENT, ACCOMPANYING WHITE PROXY CARD AND ALL OTHER DOCUMENTS
FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. The Company&rsquo;s
definitive proxy statement for the 2022 Annual Meeting of Stockholders will contain information regarding the direct and indirect interests,
by security holdings or otherwise, of the Company&rsquo;s directors and executive officers in the Company&rsquo;s securities. Information
regarding subsequent changes to their holdings of the Company&rsquo;s securities can be found in the SEC filings on Forms 3, 4, and 5,
which are available on the Company&rsquo;s website at https://ir.pharmacyte.com/all-sec-filings or through the SEC&rsquo;s website at
www.sec.gov. Information can also be found in the Company&rsquo;s Annual Report on&nbsp;Form 10-K&nbsp;for the year ended April 30, 2022
to be filed with the SEC and in subsequent filings with the SEC. Updated information regarding the identity of potential participants,
and their direct or indirect interests, by security holdings or otherwise, will be set forth in the definitive proxy statement and other
materials to be filed with the SEC in connection with the 2022 Annual Meeting of Stockholders. Stockholders will be able to obtain the
definitive proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC
at no charge at the SEC&rsquo;s website at www.sec.gov. Copies will also be available at no charge at the Company&rsquo;s website at https://ir.pharmacyte.com/all-sec-filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 73px; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Item 9.01</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Financial Statements and Exhibits. </B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Exhibits.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 73px; font-size: 10pt"><FONT STYLE="font-size: 10pt"><FONT STYLE="text-decoration: underline">Number</FONT></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><FONT STYLE="text-decoration: underline">Description</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A HREF="pharmacyte_ex9901.htm">Press Release, dated July 28, 2022, of PharmaCyte Biotech, Inc.</A></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">104</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: July 28, 2022</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>PHARMACYTE BIOTECH, INC.</B></FONT></TD></TR>
  <TR>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD></TR>
  <TR>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">&#160;</TD>
    <TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-size: 10pt">By:&#160;&#160;&#160;</FONT></TD>
    <TD STYLE="width: 48%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: underline">/s/ Kenneth L. Waggoner</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kenneth L. Waggoner</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">President and General Counsel</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>



</BODY>
</HTML>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pharmacyte_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.15pt">PharmaCyte Biotech Rebukes Iroquois&rsquo; Commencement
of Consent Solicitation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><TD STYLE="padding-right: 5.4pt"><I>7% owner Attempting to Take Control of Company Without Paying a Control Premium to Shareholders</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 10.45pt"><I>Circumvents Proper Vetting of Directors; Proposes Slate with Multiple Connections and Allegiances
to Iroquois with History of Value Destruction</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 14.95pt"><I>Proposes 15-Person Board Which is Operationally Inefficient, Violates the Bylaws, and Would Unnecessarily
Waste Company Resources</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 20.4pt"><I>Attempts to Amend Bylaws to Entrench Itself and Its Own Nominees At The Expense of All Shareholders</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.95pt"></TD><TD STYLE="width: 21.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Iroquois&rsquo; Consent Solicitation Is Full of Factual Inaccuracies and Misrepresentations</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">LAS VEGAS, NV, July 28, 2022, PharmaCyte Biotech, Inc.
(NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its
signature live-cell encapsulation technology, Cell-in-a-Box<SUP>&reg;</SUP>, today issued the following statement in response to Iroquois
Capital&rsquo;s filing of a preliminary consentstatement to commence a consent solicitation in lieu of a stockholder meeting. Iroquois
Capital is seeking the consent of the Company&rsquo;s shareholders to change various Company Bylaws, expand the size of the Company&rsquo;s
Board of Directors (Board) from 7 to 15, and elect Iroquois&rsquo; entire slate of 8 directors to the Board. The Company has serious
concerns with this recent action taken by Iroquois and portends trouble ahead for the Company and its shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">For the reasons set forth below, we implore our fellow
shareholders to rebuke the significant infringement to your shareholder rights represented by Iroquois&rsquo; proposed changes to our
Bylaws. Please ignore any &ldquo;WHITE&rdquo; consent card you may receive from Iroquois. We are not responsible for the accuracy of
any information provided by or relating to Iroquois contained in any consent solicitation materials filed or disseminated by, or on behalf
of, Iroquois or any other statements that Iroquois or its representatives have made or may otherwise make. In fact, the Iroquois consent
solicitation is riddled with misstatements. Any Iroquois mailing or communication is not from PharmaCyte; instead, it is an attempt by
Iroquois, a hedge fund with only 7% ownership, to solicit consents that are designed to enable Iroquois to take over the entire Company
and its cash position of over $80 million. We are not a private company for the benefit of one shareholder. We are a public entity working
to build shareholder value and change the landscape of on how cancer, diabetes and malignant ascites are treated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.25pt 0pt 5pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Hedge Fund With Just 7% Ownership Attempting Board Takeover
In Order to Seize Company&rsquo;s Cash Position of Over $80 million</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Should the 8 Iroquois nominees be elected to the Board,
shareholders would effectively give Iroquois, a hedge fund which owns only 7% of our Company, full control of the Company and its resources
by providing disproportionate power to one questionable stakeholder with motives and interests that appear to conflict with the interests
of the broader shareholder base.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Iroquois would not be
paying a control premium to other shareholders; instead it intends to use the consent process and changes to the Company&rsquo;s
Bylaws to entrench itself and its nominees and to use the Company and its over $80 million in cash for its own benefit. The Iroquois
slate is dominated by current or former Iroquois employees, family members of Iroquois management, and individuals who have
partnered with Iroquois multiple times in the past resulting in the destruction of shareholder value in numerous documented
instances. In fact, in 7 identified instances where Iroquois added new board members to public companies, the stocks on average
decreased over 30% within the first year. Furthermore, the troubling web of interconnecting relationships &ndash; including familial
relationships &ndash; is in direct conflict with good corporate governance and fosters &ldquo;groupthink&rdquo; which will severely
hamper the Board&rsquo;s independence and performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Iroquois&rsquo; slate of nominees has limited experience
operating a public company or a biopharma company but does, we believe, have an extensive track record of destructing value to the detriment
of shareholders. The slate of Iroquois&rsquo; nominees has no substantive experience with, or knowledge of, PharmaCyte&rsquo;s business
or technology and is being nominated solely to advance Iroquois&rsquo; short-term agenda &ndash; take control of the Company and its over
$80 million in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The current Pharmacyte Board has extensive biopharma experience
and is able to guide the Company as it continues to advance its product development. We have stated numerous times that we recognize
the importance of heightening the Board&rsquo;s capital markets knowledge to match its scientific expertise, and we are in the process
of identifying and thoroughly vetting candidates to ensure that the best people are in place to help us seize the opportunities presented
by the strength of our technology, therapies, and cash position. As a matter of fact, we have identified, and our nominating committee
is in the process of interviewing, candidates that are well- respected on Wall Street, and who have incalculable amounts of experience
in capital markets and in the biopharma industry specifically that dramatically outweighs the experience of any candidate on Iroquois&rsquo;
slate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">PharmaCyte Continues to Effectively Advance Its Strategy
Toward Lifting the FDA&rsquo;s Clinical Hold; Iroquois Has Not Provided A Strategy For The Business</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The Company is nearing the
end of its process of fulfilling the FDA&rsquo;s requests to enable the clinical hold to be lifted, and to date has successfully completed
almost two dozen studies, 12 of which have been announced since the Company secured the necessary funding to complete the work required
to satisfy the FDA&rsquo;s requests through two public offerings in concert with the Company&rsquo;s uplist to Nasdaq. Approximately
90% of the FDA&rsquo;s requests have been completed or are in process with only a few remaining to be completed. Contrary to Iroquois&rsquo;
claim that the Company &ldquo;has never publicized the actual list of requirements from the U.S. Food and Drug Administration (FDA)&rdquo;,
the Company has provided a detailed synopsis of the requests and status in its SEC filings and most recently in the appendix of the Company&rsquo;s
slide presentation available on the Company&rsquo;s website. Moreover, the Company has already commenced its two-phase pig study, which
is the last major study requested by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Our team, with the support of our experienced Board, has
made considerable progress during the past year, while controlling costs despite worldwide supply chain challenges that are affecting
FDA studies, processes and approvals across our industry. Our progress demonstrates the value of our experienced and proven team of scientific
and medical professionals who have played key roles in helping to get some of the world&rsquo;s most successful drugs through the clinic.
Iroquois&rsquo; slate has no such scientific experience and their ongoing disruptive efforts jeopardize the progress we are making, and
may result in delays in the lifting of the FDA clinical hold and destroy shareholder value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">A 15-Person Board is Irrational for a Company of
PharmaCyte&rsquo;s Size, is Inefficient, Violates our Bylaws and Adds Unnecessary Expense and Logistics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Smaller Boards, particularly for smaller public companies
like PharmaCyte, have proven to be more impactful and effective in driving shareholder value. For us, an appropriately sized Board is
approximately 7, which provides for a diversity of skill sets while remaining small enough to run efficiently for the benefit of shareholders.
Adding Board members leads directly to increased expenses related to Board fees and director insurance and inefficiencies in taking actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Iroquois is suggesting we more than double the size of
our current Board. This will equate to a substantial increase in costs &ndash; money that could better be allocated to moving our therapies
through the clinic &ndash; the clearest path to sustained shareholder value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Further, Iroquois&rsquo; proposal to increase the size
of our Board by 8 candidates violates provisions of our Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Iroquois is Trying to Dictate Who All Our Board Members
Should Be; Our Shareholders Should Beware</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">We have been engaged in
settlement discussions with Iroquois to refresh our Board with more directors with capital markets expertise. Iroquois holds just 7%
of our common stock, yet, despite this small ownership position, Iroquois is attempting to dictate our entire Board membership
including who our Board candidates should be. Having failed to offer a reasonable settlement, they now seek to expand the Board to
15 with 8 of their nominees, none of whom is familiar with or has any expertise regarding our technology and drug development
programs. Iroquois is attempting to acquire full control of the Company at little cost to itself for its own ends, at the cost of
other shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Iroquois&rsquo; Consent Solicitation Is Full of Factual
Inaccuracies And Misrepresentations; Their Intentions Should Not Be Trusted</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">For example, the statement &ldquo;On August 9, 2021, Iroquois
made its initial investment of $2.5 million in the Company in connection with a private placement offering in which the Company raised
nearly $90 million&rdquo; is misleading, and creates the false impression that Iroquois made a significant and lasting investment of $2.5
million in the Company at a high price per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">In fact, Iroquois purchased shares
and warrants for approximately $300,000 on August 9, 2021 in a $15 million public offering by the Company, and Iroquois then sold all
of the purchased shares almost immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">On August 19, 2021, Iroquois purchased shares and
warrants for approximately $2.5 million in a $70 million registered direct offering by the Company, and Iroquois then sold all of
the purchased shares that very same day. Since that sale of its entire position on August 19, 2021, Iroquois has continued to
purchase and sell the Company&rsquo;s shares, with an average acquisition price per share which we believe to be similar to the
Company&rsquo;s current trading price on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Iroquois has opportunistically acquired the Company&rsquo;s
stock at a low price, and seeks your consent to take control of the Company and its cash reserves at your expense and to your detriment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Iroquois Is Proposing Bylaw Changes to Take Over The Company
And Promote It&rsquo;s Interests While Disenfranchising Other Shareholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Our Bylaws were designed to help protect the rights of
all shareholders from the will of a single investor. Iroquois is requesting Bylaw changes to give themselves a path to take control of
our Company, including full discretion to deploy the Company&rsquo;s valuable cash, however Iroquois deems appropriate. Our cash position
is a key strategic asset supporting our growth strategy; if our cash is misallocated or squandered, our growth and product candidate development
plans are in jeopardy, which was the reason PharmaCyte uplisted to Nasdaq in the first place&mdash;to raise the necessary capital to develop
its product candidates and get the clinical hold lifted on our IND.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Our Board and management were planning, and in the early
stages of launching, many of the initiatives Iroquois is now trying to take credit for, and efforts were underway well before Iroquois
began publicly expressing grievances. We share in the frustration with the current share price, but we believe it is imperative that we
continue to dedicate the majority of our time and resources to advancing our groundbreaking technology through the clinic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">We have heard and given thoughtful
consideration and response to the opinions Iroquois has put forward, including adding additional capital markets experience to our Board.
However, we will not let one shareholder derail the Company from its ultimate mission &ndash; the continued development of and successful
clinical trials for our groundbreaking therapies &ndash; to the detriment of all other stakeholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Again, we urge our fellow shareholders
to strongly rebuke the significant infringement to your shareholder rights represented by Iroquois&rsquo; proposed changes to our Bylaws.
Please disregard any &ldquo;WHITE&rdquo; consent card that you may receive from Iroquois by taking no action at all. We are not responsible
for the accuracy of any information provided by or relating to Iroquois contained in any consent solicitation materials filed or disseminated
by, or on behalf of, Iroquois or any other statements that Iroquois or its representatives have made or may otherwise make. Any Iroquois
mailing or communication is not from PharmaCyte; instead, it is an attempt by Iroquois, a hedge fund with only 7% ownership, to solicit
consents that may enable Iroquois to take over the entire Board of PharmaCyte by changing Bylaws that were designed to protect the Company&rsquo;s
shareholders. PharmaCyte is not a private company for the benefit of one shareholder. We are a public entity working to build shareholder
value and change the landscape for how cancer, diabetes and malignant ascites are treated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Thank you for your continued support.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">About PharmaCyte Biotech</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">PharmaCyte Biotech, Inc. is a biotechnology company
developing cellular therapies for cancer, diabetes and malignant ascites based upon a proprietary cellulose-based live-cell
encapsulation technology known as &ldquo;Cell-in-a-Box<SUP>&reg;</SUP>.&rdquo; This technology is being used as a platform upon
which therapies for several types of cancer, diabetes and malignant ascites are being developed. PharmaCyte&rsquo;s therapy for
cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or
&ldquo;cancer-killing&rdquo; form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the
patient&rsquo;s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated
in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system
to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside
act as a &ldquo;bio-artificial liver&rdquo; and activate the chemotherapy drug at the site of the cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">PharmaCyte&rsquo;s candidate therapy for Type 1 diabetes
and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce and release
insulin in response to the levels of blood sugar in the human body. The encapsulation of the cell line will be done using the Cell-in-a-Box<SUP>&reg;</SUP>
technology. Once the encapsulated cells are implanted in a diabetic patient, we anticipate that they will function as a &ldquo;bio-artificial
pancreas&rdquo; for purposes of insulin production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">PharmaCyte&rsquo;s therapy for malignant ascites involves using
the same encapsulated cells PharmaCyte employs for pancreatic cancer but placing the encapsulated cells in the peritoneal cavity of a
patient and administering ifosfamide intravenously.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Safe Harbor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">This press release may contain
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs
and expectations of PharmaCyte&rsquo;s management and Board of Directors. Any statements contained in this press release which do not
describe historical facts are forward-looking statements subject to risks and uncertainties that could cause actual results, performance
and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results
include our ability to satisfactorily address the issues raised by the FDA in order to have the clinical hold on our IND removed, as
well as such other factors that are included in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities
and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we undertake no obligation to update
or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events
or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">More information about PharmaCyte Biotech can be found at https://www.PharmaCyte.com.
Information may also be obtained by contacting PharmaCyte's Investor Relations Department.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Investor Relations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">PharmaCyte Biotech, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Telephone: 917.595.2856</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Email: InvestorRelations@PharmaCyte.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 259.05pt 0pt 5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Attn: Dr. Gerald
W. Crabtree</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X 0$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#=^+VI:QX4
M;3[G1]9OH%N2XDC,I9<C!!&>G>M%_#WBV?PC;:OI'B[49-0:W6<V\^THY(SM
M'''XYK(_:!_X\=%_ZZ2?R%>E^'KJ&R\#Z==7,BQPQ6*.[L<!0%&36[=H1:.=
M*]229R'PM^(EWXHBO-/U=5.H6:>9YB)CS$S@Y [@XZ>M;]U\2?"]E?\ V"ZO
M9H;O(7R'M9 Y)Z8&WO7"?!;2)KC7-:\2^4T=G,6BM\C&[+[B1[# 'XUE^/P#
M\=M)X_Y:6G_H5-PBYM"522IIGN]M<)=6Z3(KJKC(#H5/X@\BN<U;X@^'-"NO
MLVJ7<MK*<E1);R ,!QD''-=17AO[0 _TG13_ +$@_E6=.*E*S-:LG"-T>S:;
MJ=OJUFMU:^;Y+<J9(V0D=<X(!Q5LD*"20 .235?3AC3+0#_GBG_H(KFOB/K4
MFD^$IHK4_P"G:@RV=LHZEGXS^6:E*[LBF[1NS:T'Q!I_B33VO=-D+PK*\)W#
M!#*<'_'Z&M-F"*6.< 9X&:\0^$EW<>%_&NJ^#]0?#.24]#(@YQ]5Y_ 5[A3J
M1Y961-.?-&[.2OOB5X6TR\:SOKZ6WN1C]U);2!N>G\-)!\3O"$]TML=76&5N
M@GB>/]6&!7G/Q# _X7?X>X'+VV?^_E=G\7]%L;WP'>7DL,8N+/$D,FT!AR 1
MGT.:ODC[OF1SS]ZW0] 5E=%=&#*PR"#D$5G:YKECX>T\7VH.R0&5(MRC."QP
M/PYKFOA(]Y)\.-.-X7)!<1%^OE[CM_#%8?QVN77PG8V48+-<W8^4<DA5)J5#
MW^4MSM#F/4@0P!!!!Y!'>EKA?A1XG_X2/P;"DTFZ\L<6\V3R0!\K?B/Y5?\
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M;V;-Q=.>2TK<G/TX'X4Y23CS]=A1BU+DZ;GF/P=D-A\0_$.F-P75\#_<D/\
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M-:-NQG#DO+F[G?T5A^9KO]Z'_OBBN>QTW-L #H!S1M .0!GUI:*0PI  !@
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"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
